Comparing Glaukos (NYSE:GKOS) & CardioGenics (OTCMKTS:CGNH)

Glaukos (NYSE:GKOS) and CardioGenics (OTCMKTS:CGNH) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and price targets for Glaukos and CardioGenics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	2	1	11	1	2.73
CardioGenics	0	0	0	0	0.00

Glaukos currently has a consensus price target of $133.69, indicating a potential upside of 10.26%. Given Glaukos’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Glaukos is more favorable than CardioGenics.

Profitability

This table compares Glaukos and CardioGenics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Glaukos	-36.99%	-7.00%	-5.38%
CardioGenics	N/A	N/A	N/A

Earnings & Valuation

This table compares Glaukos and CardioGenics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44 million	13.88	-$187.69 million	($3.26)	-37.20
CardioGenics	N/A	N/A	N/A	N/A	N/A

CardioGenics has lower revenue, but higher earnings than Glaukos.

Institutional and Insider Ownership

99.0% of Glaukos shares are held by institutional investors. 5.8% of Glaukos shares are held by company insiders. Comparatively, 41.4% of CardioGenics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

Glaukos has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500. Comparatively, CardioGenics has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500.

Summary

Glaukos beats CardioGenics on 6 of the 11 factors compared between the two stocks.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

About CardioGenics

CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was founded in 1997 and is headquartered in Mississauga, Canada.